Structural and functional characterization of low-molecular-weight heparins: Impact on the development of guidelines for generic products

Clinical and Applied Thrombosis/Hemostasis

Volumn 15, Issue 2, 2009, Pages 137-144

  Adiguzel, Cafer ^a   Jeske, Walter P ^a   Hoppensteadt, Debra ^a   Walenga, Jeanine M ^a   Bansal, Vinod ^a   Fareed, Jawed ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Biosimilar; Branded drugs; Generic drugs; Low molecular weight heparins

Indexed keywords

DALTEPARIN; ENOXAPARIN; GENERIC DRUG; LOW MOLECULAR WEIGHT HEPARIN;

ANTICOAGULATION; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOEQUIVALENCE; BLEEDING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLASSIFICATION; DRUG CLEARANCE; DRUG EFFICACY; DRUG ELIMINATION; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; ISCHEMIA; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; THROMBOSIS; VENOUS THROMBOEMBOLISM;

DRUGS, GENERIC; GUIDELINES AS TOPIC; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; THERAPEUTIC EQUIVALENCY; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 64549105341     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029609332727     Document Type: Article

References (26)

1. Hirsh J., Raschke R. Heparin and low-molecular-weight heparin. Chest. 2004 ; 126: 188S - 203S.
2. Alban S. Molecular weight-dependent influence of heparin on the form of tissue factor pathway inhibitor circulating in plasma. Semin Thromb Hemost. 2001 ; 27: 503-511. (Pubitemid 32989375)
3. Holmer E., Kurachi K., Soderstrom G. The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin. Biochem J. 1981 ; 193: 395-400.
4. Khorana AA, Sahni A., Altland OD, Francis CW Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight. Arterioscler Thromb Vasc Biol. 2003 ; 23: 2110-2115. (Pubitemid 37433208)
5. Bray B., Lane DA, Freyssinet JM, Pejler G., Lindahl U. Effect of saccharide chain length on thrombin inhibition by heparin cofactor II and by antithrombin. Biochem J. 1989 ; 262: 225-232.
6. Jeske WP, Walenga JM, Fareed J. Differentiating between the low molecular-weight heparins used for venous thromboembolism treatment and prophylaxis. Thromb Clin. IN PRESS.
7. Casu B., Torri G. Structural characterization of low molecular weight heparins. Semin Thromb Hemost. 1999 ; 25 (suppl 3). 17-25. (Pubitemid 29517029)
8. Walenga JM, Petitou M., Samama M., Fareed J., Choay J. Importance of a 3-O-sulfate in a heparin pentasaccharide for antithrombotic activity. Thromb Res. 1988 ; 52: 553-563.
9. Becker RC New thrombolytic, anticoagulants and platelet antagonists: the future of clinical practice. J Thromb Thrombolysis. 1999 ; 7: 195-220. (Pubitemid 29225001)
10. Antman EM, McCabe CH, Gurfinkel EP, et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation. 1999 ; 100: 1593-1601. (Pubitemid 29477267)
11. Cohen M., Demers C., Gurfinkel EP, et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med. 1997 ; 337: 447-452. (Pubitemid 27333045)
12. 2003P-0064: Withhold approval of generic Lovenox (enoxaparin sodium injection). Available at: http:// www.fda.gov/ohrms/dockets/DOCKETS/03p0064/ 03p0064.htm.
13. Criteria, and evidence to assess actual or potential bioequivalence problems. Volume 21 CFR 320. 33: Federal Registrar; 1998.
14. Samama MM, Gerotziafas GT Comparative pharmacokinetics of LMWHs. Semin Thromb Hemost. 2000 ; 26 (suppl 1). 31-38.
15. Linhardt RJ, Capila I. Heparin-protein interactions. Angew Chem. 2002 ; 41: 390-412.
16. Lindahl U., Thunberg L., Leder IG Evidence for a 3-O-sulfated D-glucosamine residue in the antithrombin-binding sequence of heparin. Proc Natl Acad Sci. 1980 ; 77: 6551-6555.
17. Petitou M., Lormeau JC, Choay J. Interaction of heparin and antithrombin III. The role of O-sulfate groups. Eur J Biochem. 1988 ; 176: 637-640.
18. Nugent MA Heparin sequencing brings structure to the function of complex oligosaccharides. Proc Natl Acad Sci. 2000 ; 97: 10301-10303.
19. Jeske WP, Neville B., Ma Q., Hoppensteadt DA, Fareed J. Effect of 1,6-anhdro bicyclic ring structure on the pharmacokinetic and pharmacodynamic behavior of low molecular weight heparin. Blood. 2004 ; 104 :Abstract 1868.
20. Jeske WP, Walenga JM, Ackerman PD, et al. Assay dependent variations in the anticoagulant and protamine sulfate neutralization profiles of generic copies of enoxaparin. Blood. 2006 ; 108: 272a.
21. Fareed J., Leong WL, Hoppensteadt DA, et al. Generic low-molecular-weight heparins: some practical considerations. Semin Thromb Hemost. 2004 ; 30: 703-713. (Pubitemid 40041606)
22. Leong WL, Hoppensteadt D. Generic forms of low molecular weight heparins: some practical considerations. Clin Appl Thromb Hemost. 2003 ; 9: 293-297. (Pubitemid 37414119)
23. Fareed J., Haas S., Sasahara A. Differentiation of low molecular weight heparins: applied and clinical considerations. Semin Thromb Hemost. 1999 ; 25 (suppl 13). 1-47.
24. Jeske WP, Walenga JM, Hoppensteadt DA, et al. Differentiating low-molecular-weight heparins based on chemical, biological and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins. Semin Thromb Hemost. 2008 ; 34: 74-85.
25. Jeske WP, Ackerman PD, Drenth A., Walenga J., Bakhos M. Generic versions of branded low molecular weight heparins can be differentiated in biologic and pharmacologic assays. J Thromb Haemost. 2007 ; 5 (suppl 2). P-M-647.
26. Jeske WP, Ma Q., Maddineni J., et al. Biochemical and pharmacologic equivalence of generic versions of low molecular weight heparins. A comparative study with innovator products. J Thromb Haemost. 2005 ; 3 (suppl 1). P1899.